MIRM — Mirum Pharmaceuticals, Inc.

Mirum Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Product Sales: Total net product sales for Q4 2025 reached $149 million, up from $99 million in Q4 2024. For the full year, net product sales were $521 million, a 55% increase from $330 million in 2024.
• Operating Expenses: Total operating expenses for Q4 were $153 million, with full-year expenses at $543 million, including R&D costs of $186 million and SG&A expenses of $257 million.
• Cash Position: The company ended 2025 with $391 million in cash and equivalents, up from $293 million at the end of 2024, reflecting positive cash flow from operations.
• Commercial Cash Contribution Margin: Approximately 55% for 2025, indicating improved profitability.

2. Strategic Updates and Business Highlights

• Product Performance: Strong sales driven by Livmarli, with $245 million in U.S. sales and $115 million internationally. The bile acid medicines contributed $161 million.
• Pipeline Advancements: Key milestones included the approval of Cholbam for CTX and the completion of enrollment in the VISTA study for volixibat in PSC. The addition of the Phase III brolobitug program for hepatitis delta virus enhances the pipeline.
• Upcoming Data: Anticipated top-line data from the volixibat VISTA study in PSC and interim results from the AZURE-1 study of brolobitug expected in 2026.

3. Forward Guidance and Outlook

• 2026 Sales Forecast: Expected net product sales between $630 million and $650 million, reflecting continued growth.
• R&D Spending: Anticipated increase in R&D expenses in 2026, primarily due to investments in the brolobitug clinical program and manufacturing preparations for a BLA submission.

4. Challenges and Points of Concern

• Market Dynamics: The company faces competitive pressures in the hepatitis delta market, with emerging therapies potentially impacting market share.
• Regulatory Risks: The need for a robust safety database for volixibat and interactions with the FDA regarding NDA submissions could pose timing risks.
• Sales Growth Deceleration: While 2025 saw significant growth, the guidance for 2026 indicates a slower growth rate (21%-25%), raising concerns about sustaining momentum.

5. Notable Q&A Insights

• Pricing Strategy for Volixibat: Management is considering pricing in relation to existing therapies but emphasizes the unique positioning of volixibat due to the lack of approved treatments for PSC.
• Study Design for PSC: Concerns were raised about the episodic nature of pruritus in PSC patients; however, management expressed confidence in the study design and patient selection.
• Market for Hepatitis Delta: The current treatment landscape is evolving, with brolobitug positioned as a potential best-in-class option, despite competition from other therapies.
• EXPAND Study Expectations: Management indicated that positive results from the EXPAND study could lead to label expansions, but emphasized the need for physician education to drive uptake in additional indications.

Overall, Mirum Pharmaceuticals is entering 2026 with a strong financial position and a promising pipeline, although it faces challenges related to market competition and regulatory requirements.